has Server used IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2018-08-29 (1 year, 23 days) and hosted in Manchester United States, server ping response time 3 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Cyclerion keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Cyclerion
2 Cyclerion therapeutics
3 Cyclerion stock
4 Cyclerion ironwood
5 Cyclerion therapeutics inc
6 Cyclerion therapeutics stock
7 Cyclerion spinoff
8 Cyclerion stock symbol
9 Cyclerion therapeutics address

Hosting Provider

Region: NH
City: Manchester
Postal Code: 03101
Latitude: 42.988498687744
Longitude: -71.465202331543
Area Code: 603
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain

New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently (6 seconds ago) (15 seconds ago) (0 seconds ago) (1 seconds ago) (6 seconds ago) (15 seconds ago) (21 seconds ago) (13 seconds ago) (3 seconds ago) (16 seconds ago) (7 seconds ago) (1 seconds ago) (0 seconds ago) (8 seconds ago) (7 seconds ago) (9 seconds ago) (40 seconds ago) (26 seconds ago) (5 seconds ago) (38 seconds ago)

Results For Websites Listing

Found 56 Websites with content related to this domain, It is result after search with search engine


09/10/2019. Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17. Read More. 08/12/2019. Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

Cyclerion | LinkedIn

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan

Cyclerion, the Planned R&D Spin-off of Ironwood

– Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2019 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into an agreement for a private placement of up to $175 million.

Cyclerion Therapeutics, Inc. (CYCN) Stock Price, Quote

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan

Ironwood, traditional drug maker, spins off edgy kid

Cyclerion is starting with about 140 employees, over half of them involved in drug discovery and development. The new Ironwood is pushing to increase sales of Linzess, Ironwood’s only drug on

Ironwood Pharmaceuticals Announces Chief Executive

– Mark Mallon to become CEO of Ironwood – – Peter Hecht, founder and current CEO of Ironwood, to become CEO of Cyclerion (R&D Co.) – – Separation on track for completion in first half of

Cyclerion Therapeutics, Inc. (CYCN) Company Profile & Facts

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its

Ironwood Announces Effectiveness of Cyclerion Form 10

– “When-issued” trading of CYCN expected to begin on Nasdaq on March 18, 2019 – – Separation completion expected April 1, 2019 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC).

Recently Analyzed Sites